ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

A Agilent Technologies

139.45
1.93 (1.40%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agilent Technologies NYSE:A NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  1.93 1.40% 139.45 140.95 138.41 139.69 1,097,924 01:00:00

Agilent Presents Thought Leader Award to Professor Diether Lambrechts

20/02/2019 4:00pm

Business Wire


Agilent Technologies (NYSE:A)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Agilent Technologies Charts.

Belgian scientist recognized for his research in cancer genomics

Agilent Technologies Inc. (NYSE: A) today announced that Professor Diether Lambrechts has received an Agilent Thought Leader Award in support of his research in cancer genomics.

Dr. Lambrechts directs the VIB-KU Leuven Center for Cancer Biology in Leuven, Belgium. He is also a professor of human genetics at KU Leuven. Dr. Lambrechts lab focuses on the discovery of genetic or epigenetic markers, either as susceptibility factors for cancer treatment development, as prognostic markers to improve the molecular genetic annotation of cancer, or as markers for targeted cancer therapies.

“Agilent continues to support transformative research of leading academic researchers—in this case, to advance our understanding of the mechanisms of resistance of tumor cells to immunotherapy,” said Kamni Vijay, Agilent vice president, and general manager of the company’s Genomics Division. “Dr. Lambrechts’ research has the potential to identify biomarkers as well as alternative drug targets. He and his team may also be able to show the way toward new companion diagnostics to help oncologists more accurately match patients with the best available treatment.”

“I am thrilled to receive this award from Agilent. This kind of support is essential to advance cancer research and discover novel biomarkers for checkpoint immunotherapy in cancer patients,” said Dr. Lambrechts. “Cancer immunotherapy has created a paradigm shift in the treatment of advanced-stage cancers, but it only delivers durable clinical responses in a relatively small fraction of cancer patients. By applying a combination of single-cell profiling methods we hope to have a major impact on patients receiving these therapies.”

The Agilent Thought Leader Award promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics and chemical analysis space. Information about previous award recipients is available on the Agilent Thought Leader Award webpage.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 14,800 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Naomi GoumilloutAgilent Technologies+1.781.266.2819naomi.goumillout@agilent.com

1 Year Agilent Technologies Chart

1 Year Agilent Technologies Chart

1 Month Agilent Technologies Chart

1 Month Agilent Technologies Chart

Your Recent History

Delayed Upgrade Clock